Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CVS Supplement Deceptively Capitalizes On Proximity To AREDS-Formula Product – Complaint

This article was originally published in The Tan Sheet

Executive Summary

CVS supplement Advanced Eye Health deceives consumers by piggy-backing off NIH study findings of a Bausch + Lomb formula found to reduce eye disease progression, says a complaint seeking class action status in California state court.

You may also be interested in...



Vision Health Supplements Blurry On AREDS Formulation – Study

A study finds claims for ocular supplements cited or relied on AREDS findings even when the products did not match the formulas assessed in the research by NIH’s National Eye Institute. The products emphasize AREDS but offer little information to consumers, they say.

Bausch & Lomb OcuVite Line Extension Used In Natl. Eye Institute Study

Promotions for Bausch & Lomb's new Ocuvite PreserVision containing vitamins C and E, beta carotene, zinc and copper likely will stress the product's clinically proven eye health benefits.

HBW Executive Decisions: Perrigo Americas, Nutraceutical International Helm Changes, ABC Farnsworth Award, More

Myos Rens hires Eric LeGrand as special advisor for sports nutrition; Perrigo Consumer Americas chief Jeff Needham will be succeeded by Rich Sorota; Nutraceutical International appoints Monty Sharma to replace Chad Clawson at the helm; American Botanical Council’s Farnsworth Award goes to Rachel Mata; and Herbalife’s John Agwunobi will be chairman as well as CEO.

Topics

Related Companies

UsernamePublicRestriction

Register

PS107445

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel